Defense Stock Domin...
Health Care: Drugs
Biosante Pharmaceuticals Inc. (BPAX: NASDAQ)
$1.15 0.01 | 0.88%
05/23/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 34.79M | 57.23M | 38.16M | 29.86M |
| Receivables | 0.00 | 0.00 | 0.00 | 64.64K |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 35.17M | 58.03M | 40.63M | 31.41M |
| Property, Plant & Equipment, Gross | 557.95K | 1.29M | 1.08M | 1.09M |
| Accumulated Depreciation & Depletion | 391.56K | 426.09K | 445.85K | 346.97K |
| Property, Plant & Equipment, Net | 166.39K | 861.36K | 635.78K | 747.98K |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 3.43M | 3.49M | 3.51M | 4.28M |
| Total Non-Current Assets | 3.60M | 4.35M | 4.14M | 5.03M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 38.77M | 62.38M | 44.77M | 36.44M |
| Accounts Payable | 1.13M | 3.15M | 4.86M | 2.46M |
| Short Term Debt | 0.00 | 0.00 | 1.11M | 0.00 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 10.59M | 7.23M | 8.18M | 3.93M |
| Long Term Debt | 0.00 | 17.34M | 17.44M | 16.68M |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 0.00 | 17.34M | 17.44M | 16.68M |
| Total Liabilities | 10.59M | 24.56M | 25.62M | 20.61M |
| Preferred Stock Equity | 391.00 | 391.00 | 391.00 | 391.00 |
| Common Stock Equity | 28.18M | 37.81M | 19.15M | 15.83M |
| Common Par | 273.13M | 255.05M | 184.78M | 135.26M |
| Additional Paid In Capital | 0.00 | 0.00 | 0.00 | 0.00 |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -244.96M | -217.24M | -165.63M | -119.43M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Capitalization | 28.18M | 55.15M | 36.58M | 32.51M |
| Total Equity | 28.18M | 37.82M | 19.15M | 15.83M |
| Total Liabilities & Stock Equity | 38.77M | 62.38M | 44.77M | 36.44M |
| Total Common Shares Outstanding | 24.49M | 18.66M | 13.96M | 9.27M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 21.76M | 16.40M | 10.99M | 5.66M |
| Diluted Weighted Shares Outstanding | 21.76M | 16.40M | 10.99M | 5.66M |
| Number of Employees | 12 | 54 | 45 | 25 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with BPAX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorHot Biotech Stocks Traded b...
- UserSaveyn walter
- User2012_03
- Userwayne120
- ContributorBreakout Stocks Of The Week...
- UserDunDon1
- Contributor6 Drug Stocks Unworthy of B...
Latest BPAX Headlines from TheStreet
- The Worst Biotech CEO of 2012 Is... 12.07.12 | 09:12 am
- Your Vote Counts: Who Is the Worst Biotech CEO of 2012? 12.04.12 | 08:12 am
- The Next Big Thing In Biotech: Worst CEO Candidates
11.23.12 | 05:11 am - 4 Biotech Stocks Under $10 Soaring Higher 09.25.12 | 02:09 pm
- 5 Biotech Stocks Under $5 Blasting Off 08.16.12 | 03:08 pm
- BioSante Execs Use Failed Libigel To Keep Paychecks Rolling In 06.11.12 | 09:06 am
- Biosante Stock Gaps Down On Today's Open (BPAX) 06.01.12 | 09:06 am
- Biotech Twitter Mailbag: Gilead, Chelsea, Keryx, Onyx, BioSante, Dendreon 02.29.12 | 06:02 am
- Transocean, Netflix, BioSante Are Market Movers 02.27.12 | 05:02 pm
- Biotech Stock Mailbag: Vivus, Chelsea, BioCryst 02.17.12 | 05:02 am
Press Releases for BPAX
- Ceregene Reports Data From Parkinson's Disease Phase 2b Study - PR Newswire 04.19.13 | 02:04 pm
- BioSante Pharmaceuticals, Inc. Sends Letter Urging Stockholders To Vote “FOR” Proposed Merger With ANI Pharmaceuticals, Inc. - Business Wire 03.19.13 | 09:03 am
- BioSante Pharmaceuticals Announces Adjournment Of Its Stockholders Meeting Until April 12, 2013 - Business Wire 03.15.13 | 04:03 pm
- Ceregene And Alzheimer's Disease Cooperative Study Group Complete Enrollment Of CERE-110 Phase 2 Trial - PR Newswire 03.13.13 | 07:03 am
- Glass, Lewis & Co., LLC Recommends Vote “FOR” BioSante/ANI Merger - Business Wire 03.04.13 | 09:03 am
- BioSante Pharmaceuticals Provides Merger Update And Reports 2012 Financial Results - Business Wire 03.01.13 | 09:03 am
- Leading Independent Proxy Advisory Firm ISS Joins Egan-Jones In Recommending “FOR” BioSante/ANI Merger - Business Wire 02.26.13 | 09:02 am
- Egan-Jones Proxy Services Recommends Stockholders Vote “FOR” BioSante And ANI Merger - Business Wire 02.19.13 | 09:02 am
- BioSante Pharmaceuticals And ANI Pharmaceuticals Announce Special Meetings Of Stockholders To Consider Proposed Merger - Business Wire 01.22.13 | 04:01 pm
- BioSante Pharmaceuticals Reports Third Quarter Financial Results And Merger Update - Business Wire 11.08.12 | 04:11 pm
Partner Headlines for BPAX
- Under Construction Rehash: Buy Acadia And Astex - Seeking Alpha 09.20.12 | 09:09 am
- 5 BioPharmas To Watch For Wednesday, September 5 - Seeking Alpha 09.05.12 | 09:09 am
- Healthcare Biz Recap: Complete Genomics CUTS Costs, Abbott Labs Teams Up - Wall St. Cheat Sheet 06.06.12 | 08:06 am
- Alimera Sciences: An Upcoming Catalyst Should Make For A Nice Stock Gain - Seeking Alpha 03.26.12 | 09:03 am
- Bio-Pharma Watch List: 2 Week Report Card - Seeking Alpha 03.12.12 | 09:03 am
- What BioSante's Balance Sheet Says About Future R&D - Seeking Alpha 03.01.12 | 08:03 am
- 12 Healthcare Companies Expecting Major February Catalysts - Seeking Alpha 02.01.12 | 07:02 am
- 3 Biotechs Hopefully To Get Rich Or Die Trying - Seeking Alpha 01.04.12 | 08:01 am
- Singular Research Drops Coverage on BioSante Pharma After LibGel Results - Benzinga 12.16.11 | 04:12 pm
- Singular Research Reiterates BioSante Pharmaceuticals Buy, Maintains PT - Benzinga 12.13.11 | 01:12 pm
